January 2003

Venture Capital: Funding Challenges

February 23, 2009

VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded. IN THE VAULT … KEN ANDERSEN. […]

Dr. Donald G. Payan — Reaching for the Stars Through Molecules

February 23, 2009

As cofounder, executive VP, and chief scientific officer of Rigel Pharmaceuticals, Dr. Donald G. Payan intends to have his company become the brightest star among those hunting for new drugs. LIFE’S BIGGEST DECISIONS OFTEN CAN BE ATTRIBUTED TO COINCIDENCE. In the mid-1960s, Dr. Payan arrived in California to study physics and math at Stanford University, […]

Addressing Pharma’s $40 Billion Challenge

February 23, 2009

Michael Perry, Ph.D., president and CEO, and Arthur Reidel, chairman, of Pharsight, outline the potential solutions and describe the remaining obstacles to successful implementation of technology as a way to unclog the pipeline.

A Community Approach

February 23, 2009

As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronted with heavy regulations and intense competition, finding ways to develop […]

Delivering on the Promise

February 23, 2009

BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict that 20% of all pharmaceuticals will involve drug-delivery formulations. Frost & Sullivan estimated the […]

Talent Pool

February 23, 2009

TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY Pharma POOL Lamberto ANDREOTTI Dr. Andrew G. BODNAR Donald J. HAYDEN Dr. James B. D. PALMER Thomas J. PICKARD David L. ZABOR Bristol-Myers Squibb Announces New Senior Leadership Team — Appoints Former GlaxoSmithKline VP as Chief Scientific Officer Bristol-Myers Squibb Co. has announced a change […]

E-Media

February 23, 2009

NEW ELECTRONIC AND WEB-BASED APPLICATIONS, SITES, AND TECHNOLOGIES PatientLinx.com Offers NEWS UPDATES BY DISEASE AND THERAPEUTIC CATEGORIES MDLinx has launched PatientLinx.com, a free Website that provides reliable clinical updates for patients. PatientLinx aggregates research by disease and therapeutic category, making access to targeted news even more readily available to patients. The 24 subspecialties include categories […]

What’s New

February 22, 2009

NEW HEALTHCARE-RELATED PRODUCTS, SERVICES, AND COMPANIES NOP World Health Forms a New Division to RESPOND TO PHARMACEUTICAL PUBLIC-RELATIONS CRISES Through a combination of in-depth therapeutic class analyses, events-driven Web research, and multi-stake holder image tracking and reputation assessment, NOP can design programs that protect companies from the fallout that accompanies negative press. NOP World Health’s […]

PharmaTrax

February 22, 2009

SALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY GENERICS SECTOR Expected to Double by 2007 According to Datamonitor, by 2007 the generics market is expected to be valued at $57 billion, more than twice its estimated value of $27 billion in 2001. Researchers at the company conclude that the generic market will continue to […]

For Art’s Sake

February 22, 2009

There are a handful of “classic” pharmaceutical healthcare ads. Ads that stand the test of time and follow the basic tenets of good advertising. Once again, Abelson-Taylor’s ad campaign for Hytrin has been identified as such a classic. According to Don Martiny, the Hytrin Balloon campaign, which debuted in 1993, is one of the best […]

PharmaOutlet

February 22, 2009

A WHOLE NEW MEANING TO JUNK MAIL If you are depressed that the only things you seem to receive in the mail are bills, there may be a cure. Last summer, some sales representatives in southern Florida allegedly orchestrated a promotional scheme, with the cooperation of one or more physician practice groups and Walgreen Co. […]

PharmaCase

February 22, 2009

Making a case for PATIENT EDUCATION Patient ed project puts pharma company on ‘Write track’ with cancer patients EVER CONSIDER PITCHING YOUR BOSS ON A LARGE-SCALE PATIENT EDUCATION PROJECT THAT: A.) WOULD BE VERY EXPENSIVE, B.) WOULD NOT DIRECTLY SUPPORT ANY OF YOUR PRODUCTS, AND C.) WOULD DEFY ANY ATTEMPT TO QUANTIFY A RETURN ON […]

What’s on your mind: Opinions

February 22, 2009

OPINIONS Information standards In the November/December issue of PharmaVOICE, we asked if the Food and Drug Administration should consider relaxing its standards for press releases about drug approvals, which currently are almost always considered a promotion. The regulatory agency issued a call for public comment May 16, 2002, after the Supreme Court said FDA restrictions […]

Raise Your Voice: Letters

February 22, 2009

LETTERS Two critical areas of success Missed Opportunities Your article on “The Patient Pipeline” highlighted many of the difficulties in patient accrual and retention. Unfortunately the solutions in my opinion missed two critical success factors. As CEO and cofounder of MCSI, the largest U.S.-based network of independent investigators and sites, I consider the shortage of […]

Letter from the Editor

February 22, 2009

Funding in a closed space The healthcare private equity market was down in 2002, and industry experts don’t expect a gr eat deal of improvement in 2003. Venture capital firms are sit ting on massive funds and are still doing deals, but according to Russell LaMontagne, president and founder of Corinth Group Communications, their energies […]

FEEDBACK